CTOs on the Move

Hillcrest Educational Centers

www.hillcrestec.org

 
Hillcrest Educational Foundation is a private not-for-profit agency that provides a range of individualized and comprehensive clinical, psychological and special education services for children, adolescents and families in Berkshire County, MA and the Northeast. The students served by Hillcrest in nonresidential and residential programs have complex psychiatric, behavioral and/or developmental disorders, including Autism Spectrum Disorders, and a variety of high-risk behaviors. The programs and services provided by the Hillcrest Educational Foundation are state licensed and certified, and Hillcrest Educational Centers, including Hillcrest Community Support Services, is accredited in behavioral health care by the Joint Commission.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

MEDTOX Scientific

MEDTOX Scientific, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. MEDTOX Scientific, Inc. is based in Saint Paul, MN. You can find more information on MEDTOX Scientific, Inc. at www.medtox.com

Taylor-DeJongh

Taylor-DeJongh is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Delmar, NY. To find more information about Taylor-DeJongh, please visit www.taylor-dejongh.com

Veltek Associates

Veltek Associates, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AirWare Labs

A globally patented adhesive-free nasal insert. Take advantage of your nasal system for optimal health. Drug-free, latex-free. All natural, instant relief.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.